Alumis Inc. focuses on TYK2 inhibitors ESK-001 and A-005, with ESK-001 in Phase 3 for plaque psoriasis. Find out why ALMS ...

Alumis and Acelyrin have filed a definitive proxy statement/prospectus with the US Securities and Exchange Commission for the proposed merger of the companies.

“The next 12-18 months will bring major milestones for Alumis, with topline data from the pivotal Phase 3 program for ESK-001 in moderate-to-severe plaque psoriasis expected in the first quarter ...

As of April 7, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum ...

In this video, Raj Chovatiya, MD, PhD, discusses findings from the phase 2 STRIDE trial presented at this year’s American ...

Shares of Alumis (NASDAQ:ALMS) traded ~14% higher in the premarket on Tuesday after the California-based biopharma announced a collaboration and licensing agreement with Japanese drugmaker Kaken ...

A potential buyer threatened to upend Alumis Inc.'s merger deal with Acelyrin Inc. as late as Monday, according to a Securities and Exchange Commission filings Thursday detailing the merger.

Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheetBoards unanimously recommend stockholders ...

SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to ...

SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision ...